Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial — Richard S. Finn (2019) | RDL Network
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Article 2019 en
Authors
RF
Richard S. Finn
BR
Baek‐Yeol Ryoo
PM
Philippe Merle
Abstract
1 min read
In this study, OS and PFS did not reach statistical significance per specified criteria. The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population.
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann‐Lii Cheng, Stephen L. Chan, T.W.C. Yau, Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martínez‐Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Cheng A.-L., Chan S.L., Yau T., Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Lim H.Y., Sadahisa Ogasawara, S. Cattan, Yee Chao, Siegel A.B., I. Martinez-Forero, Wei Z, Liu C.-C., Finn R.S.
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Cheng A.-L., Chan S.L., Yau T., Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, В. В. Бредер, Lim H.Y., Sadahisa Ogasawara, S. Cattan, Yee Chao, Siegel A.B., I. Martinez-Forero, Wei Z, Liu C.-C., Finn R.S.
Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho-Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng
Discussion(0)
No comments yet. Be the first to comment.